JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles

Objective: Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have a high propensity for thrombosis, which has been attributed to increased blood counts, endothelial cell (EC) dysfunction, and inflammation. The presence of the JAK2V617F mutation in the ECs of MPN patients has been...

Full description

Bibliographic Details
Main Authors:	Hilal Hekimoğlu, Selin Fulya Toprak, Selçuk Sözer
Format:	Article
Language:	English
Published:	Galenos Publishing House 2022-02-01
Series:	Turkish Journal of Hematology
Subjects:	jak2v617f endothelial cells microparticles extracellular genomic materials
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-57355

Similar Items

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-10-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-12-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women
by: I. A. Olkhovskiy, et al.
Published: (2019-09-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

LUNG CLEAR “SUGAR” CELL TUMOR AND JAK V617F POSITIVE ESSENTIAL THROMBOCYTHEMIA: COINCIDENCE
by: Volkan Yazak, et al.
Published: (2014-08-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
by: Hiroki Akiyama, et al.
Published: (2020-02-01)

Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review
by: Ioana Butnariu, et al.
Published: (2023-12-01)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
by: İpek Yonal, et al.
Published: (2016-05-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
by: Sophie Allain-Maillet, et al.
Published: (2020-08-01)

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
by: Naoki Mori, et al.
Published: (2023-08-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2<sup>V617F</sup> Mutation
by: Yupeng Liu, et al.
Published: (2024-06-01)

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
by: Ristić Slobodan, et al.
Published: (2015-01-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Clinical meaning of JAK2 V617F mutation in chronic myeloproliferative disorders – the first experience
by: Joško Vučković, et al.
Published: (2006-10-01)

Correlation of Thrombosis and Clinicohematological Parameters with JAK2V617F Mutation in Philadelphia-Negative CMPNs: A Study from India
by: Kanwaljeet Singh, et al.
Published: (2022-12-01)

JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation
by: Čolović Milica, et al.
Published: (2010-01-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F+ myelofibrosis
by: Yanhong Zhao, et al.
Published: (2022-08-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
by: M.E. Bjørn, et al.
Published: (2014-01-01)

Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan
by: Naoki Mori, et al.
Published: (2008-01-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages
by: Rongqing Li, et al.
Published: (2021-02-01)

JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit)
by: Zito Luca, et al.
Published: (2011-08-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation
by: Yi-zhi Jiang, et al.
Published: (2022-12-01)